Latest:
Dr Zhang on Sacituzumab Tirumotecan in Pretreated Advanced EGFR-Mutated NSCLC
Li Zhang, MD, discusses sacituzumab tirumotecan in patients with previously treated, advanced EGFR-mutated non–small cell lung cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Gregory W. Roloff, MD
Gregory Roloff, MD, is a hematologist/oncologist at the University of Chicago Medicine in Illinois
Latest:
Oncology Experts Discuss the Long-Term Effects of the COVID-19 Pandemic: With Ramez N. Eskander, MD; Rachel N. Grisham, MD; Benjamin Herzberg, MD; Kelly McCann, MD, PhD; and Gregory Roloff, MD
Experts from across oncology specialties discuss the long-term effects of the COVID-19 pandemic on patient care.
Paul Gellhaus, MD
Paul Gellhaus, MD, is a urologic oncologist, medical director of Robotic Surgery, and an associate clinical professor in the Department of Surgery at City of Hope Cancer Center Phoenix
Latest:
Dr Gellhaus on the Advantages and Limitations of Focal Therapy for Prostate Cancer
Paul Gellhaus, MD, discusses ongoing developments with focal therapy in prostate cancer and potential avenues for technological improvement.
Heather McArthur, MD, MPH
Heather McArthur, MD, MPH, FASCO, is the Clinical Director of Breast Cancer and Komen Distinguished Chair in Clinical Breast Cancer Research at University of Texas Southwestern (UTSW) Medical Center.
Latest:
Dr McArthur on Data Supporting the Ongoing Investigation of Palazestrant in ER+, HER2– Breast Cancer
Heather McArthur, MD, MPH, FASCO, discusses data from a phase 1/2 study evaluating palazestrant in ER+, HER2– advanced or metastatic breast cancer.
Andrew Ip, MD
Andrew Ip, MD, Hackensack Meridian Health’s John Theurer Cancer Center, Hackensack University Medical Center
Latest:
Beyond the Biopsy: A New Blood Test Is Redefining the Fight Against Relapsed AML
Liquid biopsy offers a revolutionary approach for detecting relapse in AML patients post-stem cell transplant, potentially enhancing early intervention.
Catherine Shu, MD
Catherine Shu, MD, is the Price Family Associate Professor of Medicine at and the clinical director of the Thoracic Medical Oncology Service at the Columbia University Herbert Irving Comprehensive Cancer Center
Latest:
VISION Data Show Promise of Tepotinib in Treatment-Naive NSCLC Harboring MET Exon 14 Skipping Mutations: With Catherine Shu, MD
Dr Shu discusses updated data from the VISION trial of tepotinib in patients with non–small cell lung cancer harboring MET exon 14 skipping mutations.
Sagar Lonial, MD, FACP, FASCO
Latest:
EHA 2025 Insights: Emerging Developments and Future Perspectives for the Multiple Myeloma Treatment Landscape
Panelists discuss how emerging combination therapies such as bispecific antibodies with chimeric antigen receptor (CAR) T cells show promising response rates in patients with heavily refractory disease, while highlighting the ongoing unmet need to improve treatment access and educate community practices on advanced therapies.